Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17572858 | 0.81 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2102575 | 0.80 | EPHX2 (0.51) | EPHX2EPHX1 | |
| SCHEMBL21600937 | 0.79 | CHRNB2 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL24802124 | 0.76 | CHRNB2 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL20030841 | 0.75 | GAA (0.40) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL3832771 | 0.73 | — | — | |
| SCHEMBL15161471 | 0.71 | CA1 (0.47) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL24654636 | 0.71 | — | — | |
| SCHEMBL15820963 | 0.70 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL19229766 | 0.70 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1866276-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1819667-A1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006102423-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006060810-A1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | CHRNB2 4786/4885CHRNA3 4829/4885CHRNA4 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.